CSL LTD
No SEC Form 4 filings for $CMXHF in the last 30 days.
See all $CMXHF insider activity →RBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.
CSL and Alentis Therapeutics have partnered to develop and commercialize lixudebart, a potential first-in-class therapy for rare kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in milestones. Lixudebart is in Phase 2 trials for AAV-RPGN and will be tested for FSGS and PSC. CSL will fund further trials and share global profits. According to the companies, lixudebart has shown promising results in early trials.
President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CMXHF (CSL LTD). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent CMXHF coverage spans financial news, regulation and corporate actions.
Positive pressure as analysts raise price target.
CSL and Alentis Therapeutics have partnered to develop and commercialize lixudebart, a potential first-in-class therapy for rare kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in milestones. Lixudebart is in Phase 2 trials for AAV-RPGN and will be tested for FSGS and PSC. CSL will fund further trials and share global profits. According to the companies, lixudebart has shown promising results in early trials.
President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
CSL (ASX:CSL; USOTC:CSLLY) has agreed with the U.S. government to lower drug prices and invest $1.5 billion in U.S. manufacturing. The deals include pricing adjustments for Medicaid and new therapies, and a manufacturing expansion in Illinois. The company expects no material impact in fiscal 2027.
AlphAI scores every news story that mentions CMXHF with an AI model for sentiment and relevance, and aggregates insider trades from CSL LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
RBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.
2 min readCSL and Alentis Therapeutics have partnered to develop and commercialize lixudebart, a potential first-in-class therapy for rare kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in milestones. Lixudebart is in Phase 2 trials for AAV-RPGN and will be tested for FSGS and PSC. CSL will fund further trials and share global profits. According to the companies, lixudebart has shown promising results in early trials.
2 min readPresident Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
3 min readCSL (ASX:CSL; USOTC:CSLLY) has agreed with the U.S. government to lower drug prices and invest $1.5 billion in U.S. manufacturing. The deals include pricing adjustments for Medicaid and new therapies, and a manufacturing expansion in Illinois. The company expects no material impact in fiscal 2027.
2 min read
